Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Sponsor
University Hospital, Bonn
Study ID
NCT00510965
Phase
PHASE2
Status
Completed

Conditions

  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in the treatment of choroidal neovascularization in underlying angioid streaks due to Pseudoxanthoma elasticum. 10 patients will receive monthly injections of the drug in one eye over a period of one year.

Key Dates

First listed
Aug 3, 2007
Start date
Aug 31, 2007
Status verified
Aug 2011
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A

Primary Outcome Measure

Best corrected visual acuity [ Time Frame: one year ]

Related Studies